US 11,672,788 B2
Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
Jia-Shiong Chen, Taipei (TW); Mu-Hsuan Yang, Taipei (TW); Yi-Hong Wu, Taipei (TW); Sz-Hao Chu, Taipei (TW); Cheng-Han Chou, Taipei (TW); Ye-Su Chao, Taipei (TW); and Chia-Nan Chen, Taipei (TW)
Assigned to Great Novel Therapeutics Biotech & Medicals Corporation, Taipei (TW)
Filed by GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS CORPORATION, Taipei (TW)
Filed on Apr. 28, 2021, as Appl. No. 17/243,378.
Claims priority of provisional application 63/018,427, filed on Apr. 30, 2020.
Prior Publication US 2021/0379032 A1, Dec. 9, 2021
Int. Cl. A61K 31/444 (2006.01); A61P 35/00 (2006.01); A61K 31/44 (2006.01); A61K 31/4406 (2006.01); C07D 213/56 (2006.01); C07D 401/12 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/44 (2013.01); A61K 31/4406 (2013.01); A61P 35/00 (2018.01); C07D 213/56 (2013.01); C07D 401/12 (2013.01)] 11 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein W and Y are each independently selected from CH and N;
R1 is each independently selected from hydrogen, halogen, C1-C3 alkyl and halogenated C1-C3 alkyl, and can be mono-, di-, tri- or tetra-substitution;
C1 and C2 are C atoms linked by a double bond;
Ar is selected from the group consisting of the following:

OG Complex Work Unit Chemistry
wherein Ar is linked to C2 via the solid line;
R2 has the same meaning as described for R1; and
R3 is hydrogen or C1-C3 alkyl;
or a pharmaceutically acceptable salt, hydrate, stereoisomer or solvate thereof.